← All trials
NCT04552379
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2020
- Primary completion
- Apr 30, 2021
- Completion date
- Dec 31, 2021
- First posted
- Sep 17, 2020
- Last posted
- Dec 2, 2020
- Enrollment
- 1240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pontificia Universidad Catolica de ChileLead sponsor
- Telethon Kids InstituteCollaborator
- University of Western AustraliaStudy chair
- University of Western AustraliaOverall official - principal investigator
- Pontificia Universidad Catolica de ChileStudy chair
- Pontificia Universidad Catolica de ChileStudy director
- Pontificia Universidad Catolica de ChileOverall official - principal investigator
- University of TorontoStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.